year 17, Issue 2 (March - April 2023)
Iran J Med Microbiol 2023, 17(2): 176-185 |
Back to browse issues page
Neda Jalalvand1 
, Davoud Esmaeili 2, Mohammad Mehdi Moghani Bashi1 , Mohamad Reiszadeh3 , Sirous Naeimi1
, Davoud Esmaeili 2, Mohammad Mehdi Moghani Bashi1 , Mohamad Reiszadeh3 , Sirous Naeimi1
1- Department of Genetics, Faculty of Basic Sciences, Kazerun Branch, Islamic Azad University, Kazerun, Iran
2- Department of Microbiology and Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran , esm114@gmail.com
3- Associate Professor of Surgery, School of Medicine, Trauma Research Center, Bqiyatallah al-Azam Hospital, Baqiyatallah University of Medical sciences, Tehran, Iran
2- Department of Microbiology and Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran , esm114@gmail.com
3- Associate Professor of Surgery, School of Medicine, Trauma Research Center, Bqiyatallah al-Azam Hospital, Baqiyatallah University of Medical sciences, Tehran, Iran
Abstract: (1540 Views)
Background and Aim: Conventional anti-cancer treatments, such as surgery, chemotherapy, radiation therapy, etc., are linked to antimicrobial resistance (AMR) and have negative effects on healthy tissues. The flow cytometry technique was used in this study to evaluate the effectiveness of a modified anti-cancer peptide in treating the AGS gastric cancer cell line.
Materials and Methods: This study used bioinformatics software to determine the EntA-PynR-Lac gene sequence. The engineered E. coli BL21 bacterium was used to express recombinant proteins derived from the synthesized fusion gene cloned into the pET22b expression vector. A recombinant protein was designed, and its three-dimensional structure and stability were evaluated. Using Western blotting and nickel column chromatography, the recombinant protein was confirmed and purified. In addition, the MTT technique was used to determine the cell lethality of various concentrations of the recombinant protein in AGS cells. Flow cytometry was used to determine the level of apoptosis in AGS cells treated with the desired protein concentrations.
Results: According to the results of the MTT test, the 80µg/mL concentration of recombinant protein showed significant cytotoxic effects on the AGS cell line. Furthermore, using flow cytometry, it was found that cancer cells treated with this concentration of recombinant protein exhibited higher rates of total apoptosis than untreated cancer cells.
Conclusion: Inhibition of proliferation and growth of gastric cancer cells by this recombinant protein has been shown to be effective. The anti-apoptotic characteristics of the fusion protein make it useful for both therapeutic and preventative purposes when treating cancer cells.
Type of Study: Original Research Article |
Subject:
Medical Bacteriology
Received: 2022/06/30 | Accepted: 2023/01/28 | ePublished: 2023/03/30
Received: 2022/06/30 | Accepted: 2023/01/28 | ePublished: 2023/03/30
References
1. Pappas-Gogos G, Tepelenis K, Fousekis F, Katsanos K, Pitiakoudis M, Vlachos K. The Implication of Gastric Microbiome in the Treatment of Gastric Cancer. Cancers. 2022;14(8):2039. [DOI:10.3390/cancers14082039] [PMID] [PMCID]
2. Park HS, Hong NR, Ahn TS, Kim H, Jung MH, Kim BJ. Apoptosis of AGS human gastric adenocarcinoma cells by methanolic extract of Dictamnus. Pharmacogn Mag. 2015;11(Suppl 2):S329. [DOI:10.4103/0973-1296.165994] [PMID] [PMCID]
3. Molujin AM, Abbasiliasi S, Nurdin A, Lee P-C, Gansau JA, Jawan R. Bacteriocins as Potential Therapeutic Approaches in the Treatment of Various Cancers: A Review of In Vitro Studies. Cancers. 2022;14(19):4758. [DOI:10.3390/cancers14194758] [PMID] [PMCID]
4. Wang S-M, Zhang L-W, Fan R-B, Han X, Yi H-X, Zhang L-L, et al. Induction of HT-29 cells apoptosis by lactobacilli isolated from fermented products. Res Microbiol. 2014;165(3):202-14. [DOI:10.1016/j.resmic.2014.02.004] [PMID]
5. Kumar B, Balgir P, Kaur B, Mittu B, Chauhan A. In vitro cytotoxicity of native and rec-pediocin CP2 against cancer cell lines: a comparative study. Pharm Anal Acta. 2012;1(6). [DOI:10.4172/2153-2435.1000183]
6. López-Cuellar MdR, Rodríguez-Hernández A-I, Chavarría-Hernández N. LAB bacteriocin applications in the last decade. Biotechnol Biotechnol Equip. 2016;30(6):1039-50. [DOI:10.1080/13102818.2016.1232605]
7. Manoharan M, Balasubramaniam TS. An Extensive Review on Production, Purification, and Bioactive Application of Different Classes of Bacteriocin. J Trop Biotechnol Biodivers. 2022;7(3):72735. [DOI:10.22146/jtbb.72735]
8. Baindara P, Korpole S, Grover V. Bacteriocins: perspective for the development of novel anticancer drugs. Appl Microbiol Biotechnol. 2018;102(24):10393-408. [DOI:10.1007/s00253-018-9420-8] [PMID]
9. Saif M, Makrilia N, Zalonis A, Merikas M, Syrigos K. Gastric cancer in the elderly: an overview. Eur J Surg Oncol. 2010;36(8):709-17. [DOI:10.1016/j.ejso.2010.05.023] [PMID]
10. Jalalvand N, Esmaeili D, Raiszadeh M, Naeimi S. Evaluation of Physicochemical Activity of Anticancer Fusion Proteins; Enterocin A-R type pyocin-Lactocin-Ligand Against Gastric Cancer Cell Line by Real-Time RT PCR Technique. Int J Pept Res Ther. 2021;27(2):1167-75. [DOI:10.1007/s10989-021-10158-3]
11. Choubini E, Habibi M, Khorshidi A, Ghasemi A, Karam MRA, Bouzari S. A novel multi-peptide subunit vaccine admixed with AddaVax adjuvant produces significant immunogenicity and protection against Proteus mirabilis urinary tract infection in mice model. Mol Immunol. 2018;96:88-97. [DOI:10.1016/j.molimm.2018.03.001] [PMID]
12. Asadi KM, Oloomi M, Habibi M, Bouzari S. Cloning of fimH and fliC and expression of the fusion protein FimH/FliC from Uropathogenic Escherichia coli (UPEC) isolated in Iran. Iran J Microbiol. 2012;4(2):55.
13. Yoon SH, Kim SK, Kim JF. Secretory production of recombinant proteins in Escherichia coli. Recent Pat Biotechnol. 2010;4(1):23-9. [DOI:10.2174/187220810790069550] [PMID]
14. Bornhorst JA, Falke JJ. Purification of proteins using polyhistidine affinity tags. Meth Enzymol. 3262000. p. 245-54. [DOI:10.1016/S0076-6879(00)26058-8] [PMID]
15. Yousefy Z, Esmaeili D, Goudarzi H. Cloning and the expression of the protein fusion enterocin-nisin-epidermicin T as a candidate for the treatment of gastric cance (vol 20, 100751, 2020). Gene Rep. 2021;24:1. [DOI:10.1016/j.genrep.2021.101087]
16. Pirkhezranian Z, Tanhaeian A, Mirzaii M, Sekhavati MH. Expression of Enterocin-P in HEK platform: evaluation of its cytotoxic effects on cancer cell lines and its potency to interact with cell-surface glycosaminoglycan by molecular modeling. Int J Pept Res Ther. 2020;26(3):1503-12. [DOI:10.1007/s10989-019-09956-7]
17. Yusuf MA, Ichwan S, Haziyamin T, Hamid A. Anti-proliferative activities of purified bacteriocin from Enterococcus mundtii strain C4L10 isolated from the caecum of Malaysian non-broiler chicken on cancer cell lines. Int J Pharm Pharm Sci. 2014;7:334-7.
18. Paiva AD, de Oliveira MD, de Paula SO, Baracat-Pereira MC, Breukink E, Mantovani HC. Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activity. Microbiology. 2012;158(11):2851-8. [DOI:10.1099/mic.0.062190-0] [PMID]
19. Bagci E, Vodovotz Y, Billiar T, Ermentrout G, Bahar I. Bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys J. 2006;90(5):1546-59. [DOI:10.1529/biophysj.105.068122] [PMID] [PMCID]
20. Ahmadi S, Ghollasi M, Hosseini HM. The apoptotic impact of nisin as a potent bacteriocin on the colon cancer cells. Microb Pathog. 2017;111:193-7. [DOI:10.1016/j.micpath.2017.08.037] [PMID]
21. Ankaiah D, Esakkiraj P, Perumal V, Ayyanna R, Venkatesan A. Probiotic characterization of Enterococcus faecium por1: cloning, over expression of Enterocin-A and evaluation of antibacterial, anti-cancer properties. J Funct Foods. 2017;38:280-92. [DOI:10.1016/j.jff.2017.09.034]
22. Ankaiah D, Palanichamy E, Antonyraj CB, Ayyanna R, Perumal V, Ahamed SIB, et al. Cloning, overexpression, purification of bacteriocin enterocin-B and structural analysis, interaction determination of enterocin-A, B against pathogenic bacteria and human cancer cells. Int J Biol Macromol. 2018;116:502-12. [DOI:10.1016/j.ijbiomac.2018.05.002] [PMID]
23. Arunmanee W, Ecoy GAU, Khine HEE, Duangkaew M, Prompetchara E, Chanvorachote P, et al. Colicin N mediates apoptosis and suppresses integrin-modulated survival in human lung cancer cells. Molecules. 2020;25(4):816. [DOI:10.3390/molecules25040816] [PMID] [PMCID]
24. Chumchalova J, Šmarda J. Human tumor cells are selectively inhibited by colicins. Folia Microbiol. 2003;48(1):111-5. [DOI:10.1007/BF02931286] [PMID]
25. Nami Y, Abdullah N, Haghshenas B, Radiah D, Rosli R, Yari Khosroushahi A. A newly isolated probiotic E nterococcus faecalis strain from vagina microbiota enhances apoptosis of human cancer cells. J Appl Microbiol. 2014;117(2):498-508. [DOI:10.1111/jam.12531] [PMID]
26. Abdi-Ali A, Worobec E, Deezagi A, Malekzadeh F. Cytotoxic effects of pyocin S2 produced by Pseudomonas aeruginosa on the growth of three human cell lines. Can J Microbiol. 2004;50(5):375-81. [DOI:10.1139/w04-019] [PMID]
27. Watanabe T, Saito H. Cytotoxicity of pyocin S2 to tumor and normal cells and its interaction with cell surfaces. Biochim Biophys Acta Gen Subj. 1980;633(1):77-86. [DOI:10.1016/0304-4165(80)90039-2] [PMID]
28. Kim JY, Woo HJ, Kim Y-S, Kim KH, Lee HJ. Cell cycle dysregulation induced by cytoplasm of Lactococcus lactis ssp. lactis in SNUC2A, a colon cancer cell line. Nutr Cancer. 2003;46(2):197-201. [DOI:10.1207/S15327914NC4602_13] [PMID]
29. Fathizadeh H, Saffari M, Esmaeili D, Moniri R, Mahabadi JA. Anticancer effect of enterocin A-colicin E1 fusion peptide on the gastric cancer cell. Probiotics Antimicrob Proteins. 2021;13(5):1443-51. [DOI:10.1007/s12602-021-09770-y] [PMID]
30. Fathizadeh H, Saffari M, Esmaeili D, Moniri R, Salimian M. Evaluation of antibacterial activity of enterocin A-colicin E1 fusion peptide. Iran J Basic Med Sci. 2020;23(11):1471.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |